research use only
Cat.No.S7758
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|
In vitro |
DMSO
: 100 mg/mL
(131.26 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 761.84 | Formula | C39H43N3O11S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 114899-77-3 | -- | Storage of Stock Solutions |
|
|
| In vitro |
This compound can block EWS-FLI1 transcription factor activity, suppress Werner syndrome protein (WRN) expression and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. |
|---|---|
| In vivo |
In Tumor-Bearing Mice, trabectedin does not have an impact on the functional activity of MDSC but does significantly reduce the number of Ly6Chigh cells, the most suppressive subset. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06050434 | Recruiting | Soft Tissue Sarcoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|PharmaMar |
October 31 2023 | -- |
| NCT05868889 | Completed | Ovarian Cancer |
Grupo Español de Investigación en Cáncer de Ovario |
October 21 2021 | -- |
| NCT05597917 | Recruiting | Soft Tissue Sarcoma |
Universität Münster|Anturec Pharmaceuticals GmbH |
October 26 2021 | Phase 3 |
| NCT04979442 | Terminated | Dedifferentiated Liposarcoma |
Rain Oncology Inc |
July 14 2021 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.